HPV Genotype Attribution and Disease Burden of Anal Cancer in China
Not yet recruiting
- Conditions
- Anal Cancer
- Registration Number
- NCT06670495
- Lead Sponsor
- Fudan University
- Brief Summary
To demonstrate HPV prevalence and its genotype distributions in anal cancer in China and to describe demographic and clinical features of HPV-related anal cancer in China; To describe the epidemiological characteristics ,trends and of disease burden of anal cancer in China
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- (1) Patients diagnosed with anal cancers, (2) Patients without radiation or chemotherapy prior to specimen collection;
Exclusion Criteria
- (1) Patients with HIV infection, (2) Patients with immunosuppression after solid organ transplantation, (3) Those who do not agree to specimen collection and testing, (4) For retrospective study cases, those who without specimen.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence and types of distribution of HPV From enrollment to pre-treatment Incidence of anal-cancers-associated complications From enrollment to pre-treatment with or without HPV infection by subgroups of sex, age at diagnosis, sexual orientation, and stage at diagnosis (Stage I, II, III, IV, unknown)
Routine laboratory testing results From enrollment to pre-treatment
- Secondary Outcome Measures
Name Time Method Mortality rate of anal cancer in China From enrollment to pre-treatment overall and for 5-year calendar periods 2001-2005, 2006-2010, and 2011-2015
Annual percentage changes (APCs) and average APCs (AAPCs) From enrollment to pre-treatment Incidence rates of anal cancer in China From enrollment to pre-treatment overall and for 5-year calendar periods 2001-2005, 2006-2010, and 2011-2015